New anti-Leishmania agent

researcher's name
about researcher NAKAO, Yoichi Professor
Faculty of Science and Engineering
research field
Biomolecular chemistry


Leishmaniasis is a zoonotic, tropical infectious disease transmitted to humans through sandflies. It has infected 12 million people in 88 regions, and it is estimated that 2 million people become infected every year. Without treatment, leishmaniasis attacks the internal organs resulting in a 90% mortality rate.


“Cristaxenicin A,” a new chemical compound with anti-Leishmania properties


The search for target molecules in the development of drugs to treat protozoan diseases, livestock drugs and other agents


Current treatments involve the use of antimony formulas, but it has side effects, and protozoans with resistance have begun to appear. Our chemical compound has a chemical structure that is completely different from traditional drugs, and it is believed to work through a totally different mechanism. It has high selective toxicity, and there are great expectations for it as an antiprotozoal drug with low toxicity.

purpose of providing seeds

Sponsord research, Collaboration research, Technical consultation


  • The Leishmania protozoan, equipped with GFP (photo provided courtesy of Yasuyuki Goto, Prof., The University of Tokyo)
  • The life cycle of the Leishmania protozoan (provided courtesy of Yasuyuki Goto, Prof., The University of Tokyo)
  • Cristaxenicin A

same researcher's seeds

  • Natural marine chemical compounds as materials for drugs As a tool in chemical epigenetics
  • Neuronal differentiation inducer
  • Drug for epigenomic disruption caused by hyperglycemia
  • Natural compounds affecting cell differentiation
posted: 2014/05/21